McCaffrey P, Strobel G. Philadelphia: European trial of Alzhemed ends, marketing morphs to supplement. Alzheimer Research Forum. November 19, 2007. Available at: www.alzforum.org/new/detail.asp?id=1691. (Accessed 26 May 2009).
Abushakra S, Porsteinsson A, Scheltens P, et al. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer's disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4(3):149-156. View abstract.
Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7(1):102-11. View abstract.
Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007;4:473-8. View abstract.
Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67:1757-63. View abstract.
Alzheimer's Association Statement: Vivimind supplement for "protecting memory function." Alzheimer's Association, Chicago, IL. September 2008. Available at: www.alzforum.org/new/Vivimind.pdf. (Accessed 26 May 2009).
Bossú P, Salani F, Ciaramella A, et al. Anti-inflammatory effects of homotaurine in patients with amnestic mild cognitive impairment. Front Aging Neurosci. 2018;10:285. View abstract.
Fariello RG, Golden GT, Pisa M. Homotaurine (3 aminopropanesulfonic acid; 3APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid. Neurology 1982;32:241-5. View abstract.
Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13(6):550-7. View abstract.
Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28:537-47. View abstract.
Giotti A, Luzzi S, Spagnesi S, Zilletti L. Homotaurine: a GABAB antagonist in guinea-pig ileum. Br J Pharmacol 1983;79:855-62. View abstract.
Greenberg SM, Rosand J, Schneider AT, et al. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 2006;20:269-74. View abstract.
Marino PF, Rossi GCM, Campagna G, et al. Effects of citicoline, homotaurine, and vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: A preliminary study. Molecules. 2020 Nov 29;25(23):5614. View abstract.
Olive MF, Nannini MA, Ou CJ, et al. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol 2002;437:55-61. View abstract.
Paakkari P, Paakkari I, Karppanen H, Paasonen MK. Mechanisms of the inhibitory cardiovascular effects of taurine and homotaurine. Acta Med Scand Suppl 1983;677:134-7. View abstract.
Ricciardi L, De Nigris F, Specchia A, Fasano A. Homotaurine in Parkinson's disease. Neurol Sci. 2015;36(9):1581-7. View abstract.
Rossi GCM, Rolle T, De Silvestri A, et al. Multicenter, Prospective, Randomized, Single Blind, Cross-Over Study on the Effect of a Fixed Combination of Citicoline 500 mg Plus Homotaurine 50 mg on Pattern Electroretinogram (PERG) in Patients With Open Angle Glaucoma on Well Controlled Intraocular Pressure. Front Med (Lausanne) 2022;9:882335. View abstract.
Ruiz de Valderas RM, Serrano MI, Serrano JS, Fernandez A. Effect of homotaurine in experimental analgesia tests. Gen Pharmacol 1991;22:717-21. View abstract.
Serrano I, Ruiz RM, Serrano JS, Fernandez A. GABAergic and cholinergic mediation in the antinociceptive action of homotaurine. Gen Pharmacol 1992;23:421-6. View abstract.
Serrano MI, Serrano JS, Asadi I, et al. Role of K+ channels in homotaurine-induced analgesia. Fundam Clin Pharmacol 2001;15:167-73. View abstract.
Serrano MI, Serrano JS, Fernandez A, et al. GABA(B) receptors and opioid mechanisms involved in homotaurine-induced analgesia. Gen Pharmacol 1998;30:411-5. View abstract.
Singla R, Mishra A, Joshi R, et al. Homotaurine ameliorates the core ASD symptomatology in VPA rats through GABAergic signaling: Role of GAD67. Brain Res Bull 2022;190:122-133. View abstract.
Spalletta G, Cravello L, Gianni W, et al. Homotaurine effects on hippocampal volume loss and episodic memory in amnestic mild cognitive impairment. J Alzheimers Dis. 2016;50(3):807-16. View abstract.
Tian J, Dang H, O'Laco KA, et al. Homotaurine treatment enhances CD4 + and CD8 + regulatory T cell responses and synergizes with low-dose anti-CD3 to enhance diabetes remission in Type 1 diabetic mice. Immunohorizons. 2019;3(10):498-510. View abstract.
Tian J, Dang H, Wallner M, Olsen R, Kaufman DL. Homotaurine, a safe blood-brain barrier permeable GABA
<sub>A</sub>-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Sci Rep. 2018;8(1):16555. View abstract.
Toppi E, Sireno L, Lembo M, et al. IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment. Front Immunol 2022;13:813951. View abstract.
Wong GT. FDA deems US Alzhemed trial results inconclusive. Alzheimer Research Forum. August 28, 2007. Available at: www.alzforum.org/new/detail.asp?id=1647. (Accessed 26 May 2009).
Wright TM. Tramiprosate. Drugs Today (Barc) 2006;42:291-8. View abstract.